Skip to main content

IMUX

Stock

IMUX

Stock
Health Care
Biotechnology

Performance overview

IMUX Price
Price Chart

Forward-looking statistics

Beta
1.19
Risk
71.04%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Company info

SectorHealth Care
IndustryBiotechnology
Employees67
Market cap$110.8M

Fundamentals

Enterprise value$53.5M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity-0.18

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.95
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$2M
Avg trading volume (10 day)$2M
Put-call ratio

Macro factor sensitivity

Growth-2.0
Credit+7.6
Liquidity+0.3
Inflation-2.2
Commodities-2.1
Interest Rates-0.0

Valuation

Dividend yield0.00%
PEG Ratio-1.14
Price to sales
P/E Ratio-1.14
Enterprise Value to Revenue
Price to book-13.94

Upcoming events

Next earnings dayMay 16, 2025
Next dividend day
Ex. dividend day

News

Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data

Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.

Zacks Investment Research (April 6, 2023)
Immunic, University Medical Center Goettingen Ink Licensing Pact For Combination Viral Infection Treatments

Immunic Inc (NASDAQ: IMUX) has executed an in-license agreement with the University Medical Center Goettingen covering the combination of DHODH inhibitors and nucleoside analogs to treat viral infections (COVID-19 and Influenza).  The terms of the agreement were not disclosed.

Benzinga (September 22, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free